Live price temporarily unavailable.
Sarepta Therapeutics (SRPT) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $5.42M | $154.6M | $301.0M | $380.8M | $540.1M | $701.9M | $933.0M | $1.24B | $1.90B | $2.20B |
| Growth (year over year) | +332.6% | +2751.6% | +94.7% | +26.5% | +41.8% | +30.0% | +32.9% | +33.3% | +53.0% | +15.6% |
| Gross profit | $5.29M | — | — | — | — | — | — | — | — | $2.17B |
| Gross margin | 97.6% | — | — | — | — | — | — | — | — | 98.8% |
| Operating income | −$266.7M | −$171.6M | −$343.6M | −$705.6M | −$564.2M | −$459.7M | −$536.2M | −$267.8M | $218.1M | −$699.8M |
| Operating margin | −4920.3% | −111.0% | −114.1% | −185.3% | −104.5% | −65.5% | −57.5% | −21.5% | 11.5% | −31.8% |
| Net income | −$267.3M | −$50.7M | −$361.9M | −$715.1M | −$554.1M | −$418.8M | −$703.5M | −$536.0M | $235.2M | −$713.4M |
| Net margin | −4930.2% | −32.8% | −120.2% | −187.8% | −102.6% | −59.7% | −75.4% | −43.1% | 12.4% | −32.5% |
| EPS (diluted) | −$5.49 | −$0.86 | −$5.46 | −$9.71 | −$7.11 | −$5.15 | −$8.03 | −$5.80 | $2.34 | −$7.13 |
| Balance sheet | ||||||||||
| Cash and equivalents | $122.4M | $599.7M | $370.8M | $835.1M | $1.50B | $2.12B | $966.8M | $428.4M | $1.10B | $801.3M |
| Total assets | $424.1M | $1.31B | $1.64B | $1.82B | $2.98B | $3.15B | $3.13B | $3.26B | $3.96B | $3.35B |
| Total liabilities | $87.4M | $518.7M | $609.8M | $1.00B | $2.22B | $2.22B | $2.74B | $2.41B | $2.44B | $2.21B |
| Long-term debt | $17.7M | $431.1M | $420.6M | — | — | $563.7M | $1.54B | $1.24B | $1.14B | $829.0M |
| Shareholders' equity | $336.7M | $789.2M | $1.03B | $818.2M | $761.8M | $928.0M | $384.9M | $859.3M | $1.53B | $1.14B |
| Cash flow | ||||||||||
| Operating cash flow | −$245.8M | −$232.0M | −$388.7M | −$456.5M | $107.5M | −$443.2M | −$325.3M | −$501.0M | −$205.8M | −$205.5M |
| Capital expenditure | $5.34M | $12.0M | $61.2M | $59.6M | $82.2M | $38.5M | $30.8M | $76.1M | $137.0M | $102.0M |
| Free cash flow | −$251.2M | −$244.0M | −$449.8M | −$516.1M | $25.3M | −$481.7M | −$356.2M | −$577.1M | −$342.7M | −$307.5M |
| Share buybacks | — | — | — | — | — | — | — | $0 | $0 | $25.0M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $467.2M | $658.4M | $744.9M | $611.1M | $399.4M | $442.9M | $730.8M | $401.3M |
| Growth (year over year) | +40.8% | +65.9% | +80.2% | +68.4% | −14.5% | −32.7% | −1.9% | −34.3% |
| Gross profit | $338.1M | — | $474.0M | $360.6M | $219.3M | — | — | — |
| Gross margin | 72.4% | — | 63.6% | 59.0% | 54.9% | — | — | — |
| Operating income | $22.2M | $161.7M | −$300.4M | $115.6M | −$103.4M | −$411.6M | $358.4M | $13.3M |
| Operating margin | 4.8% | 24.6% | −40.3% | 18.9% | −25.9% | −92.9% | 49.0% | 3.3% |
| Net income | $33.6M | $159.0M | −$447.5M | $196.9M | −$50.6M | −$412.2M | $331.0M | −$4.89M |
| Net margin | 7.2% | 24.2% | −60.1% | 32.2% | −12.7% | −93.1% | 45.3% | −1.2% |
| EPS (diluted) | $0.34 | $1.56 | −$4.60 | $1.89 | −$0.50 | −$3.92 | $2.88 | −$0.05 |
| Balance sheet | ||||||||
| Cash and equivalents | $197.9M | $1.10B | $240.9M | $510.6M | $613.1M | $801.3M | $464.4M | $571.1M |
| Total assets | $3.60B | $3.96B | $3.47B | $3.68B | $3.49B | $3.35B | $3.18B | $3.19B |
| Total liabilities | $2.38B | $2.44B | $2.32B | $2.32B | $2.17B | $2.21B | $1.67B | $1.66B |
| Long-term debt | $1.23B | $1.14B | — | — | $140.5M | $829.0M | $838.2M | $847.6M |
| Shareholders' equity | $1.22B | $1.53B | $1.19B | $1.40B | $1.32B | $1.14B | $1.51B | $1.53B |
| Cash flow | ||||||||
| Operating cash flow | −$70.7M | $92.0M | −$583.4M | $261.3M | −$14.6M | $131.2M | −$202.7M | $197.1M |
| Capital expenditure | $37.3M | $38.1M | $43.7M | $31.8M | $22.9M | $3.59M | $2.08M | $555.0K |
| Free cash flow | −$108.0M | $54.0M | −$627.1M | $229.5M | −$37.5M | $127.6M | −$204.8M | $196.5M |
| Share buybacks | $0 | $0 | — | — | $0 | $0 | — | — |
From Sarepta Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.
Source: Wikipedia — Sarepta Therapeutics
No recent news mentioning Sarepta Therapeutics in our feed yet.